Get started
Author

Haisong Ju

Observed names: H Ju, H. Ju
ORCID: 0000-0002-3512-7285
Observed ORCID: 0000-0002-3512-7285
OpenAlex ID: A5109647995
Modification of the extracellular matrix following myocardial infarction monitored by FTIR spectroscopy
1996 · Kan-Zhi Liu, Michael Jackson, et al. · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 108
Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction
1997 · H Ju · Cardiovascular Research · 93
PDF
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma
2025 · Danny Rischin, Sandro Porceddu, et al. · New England Journal of Medicine · 88
Altered mRNA Abundance of Calcium Transport Genes in Cardiac Myocytes Induced by Angiotensin II
1996 · H Ju · Journal of Molecular and Cellular Cardiology · 52
Antiproliferative and antifibrotic effects of mimosine on adult cardiac fibroblasts1Previously published in abstract form: Circulation 94(8) (1996) I 355.1
1998 · Haisong Ju, Jianming Hao, et al. · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · 48
PDF
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · O Abani, A Abbas, et al. · The Lancet Diabetes & Endocrinology · 41
PDF
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · Saul N Faust, Richard Haynes, et al. · The Lancet Child & Adolescent Health · 39
PDF
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases · 12
PDF
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O. Abani, A. Abbas, et al. · EClinicalMedicine · 5
1660P Adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma: Evaluating dosing intervals in a phase III trial
2025 · D. Rischin, S. Porceddu, et al. · Annals of Oncology
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · O Abani, A Abbas, et al. · The Lancet Infectious Diseases
PDF
Works count: 14
Citation count: 543
H-index: 10
I10-index: 10
Year
Topic
Type